NLS-133 for Male Birth Control

This trial explores a new male birth control treatment, NLS-133, which combines two already approved drugs. The goal is to assess its safety and effectiveness in reducing semen volume and sperm count compared to a current medication or a placebo (a pill with no active drug). It suits healthy men who can provide semen samples, have normal sperm counts, and are not taking medications that affect sperm production. Researchers will monitor participants for any side effects and gather feedback on their experience with the treatment. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important advancements in male contraception.

The trial requires that you do not use certain medications during participation, such as sex hormones, testosterone, anabolic steroids, and some others. If you are taking any of these, you would need to stop them to join the study.

Research shows that NLS-133, a male birth control treatment, consists of two drugs already approved by the FDA. This indicates that each component of NLS-133 has been deemed safe for other uses. Although NLS-133 remains in the early testing stages for this specific purpose, the approval of its components can offer some reassurance about its safety.

Additionally, other non-hormonal male contraceptives, such as YCT-529, have passed initial safety tests in humans. These studies found that such treatments are safe and well-tolerated, which adds confidence, even though YCT-529 is a different treatment.

Unlike the standard male birth control options that primarily involve barrier methods like condoms or permanent solutions such as vasectomies, NLS-133 is a promising new approach because it combines two FDA-approved drugs to target male fertility. This treatment acts as an alpha-1-adrenergic receptor antagonist, which is different from typical hormonal methods used in female contraceptives. Researchers are excited about NLS-133 because it offers a potentially reversible, non-hormonal method of contraception for men, which could broaden birth control options and provide a new level of control over reproductive health.

Research has shown that NLS-133, a combination of two FDA-approved drugs, could serve effectively as a male contraceptive. In this trial, participants will receive either NLS-133, a placebo, or an active control. Similar non-hormonal contraceptives have proven highly effective, with some studies showing up to 99% success in animals. Earlier research demonstrated that treatments like NLS-133 significantly lowered sperm counts, a crucial factor in preventing pregnancy. Other male contraceptives have shown low failure rates, between 1.4% and 3.4%, suggesting that NLS-133 might be equally effective. These findings indicate that NLS-133 could be a reliable option for male birth control.¹³⁶⁷⁸